CARM
Carisma Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.00
−22.22%Next report
Analyst consensus
- Next report date
- Nov 5, 2026
- EPS estimate
- -$0.12
- Revenue estimate
- $4.7M
Latest reported
- Last report date
- Nov 12, 2025
- EPS actual
- $1.07
- EPS estimate
- —
- Revenue actual
- —
- Revenue estimate
- —
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 4
- EPS misses (12Q)
- 5
- EPS in line (12Q)
- 2
- Avg surprise (4Q)
- -46.7%
- Revenue beats (12Q)
- 4
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 5, 2026